ARS Pharmaceuticals IPO

ARS pharmaceuticals is developing an intranasal epinephrine spray for patients at-risk of severe allergic reactions to food, medications and insect bites that could lead to anaphylaxis.

Register for Details

For more details on financing and valuation for ARS Pharmaceuticals, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

What is ARS Pharmaceuticals's ticker symbol?

SPRY

What is ARS Pharmaceuticals's stock price?

3.75 as of 9/26/23

ARS Pharmaceuticals Funding Rounds and IPO Valuation

Date Funding Round Funding Raised Price per Share IPO Valuation
8/31/2021 Series D $55MM raised $XXX.XX $XXX.XX
9/14/2018 Series C $20.15MM raised $XXX.XX $XXX.XX
4/30/2018 Series B $1,000K raised $XXX.XX $XXX.XX
4/30/2016 Series A $396.84K raised $XXX.XX $XXX.XX
Based on primary financings
Powered by Forge Data

Learn more about ARS Pharmaceuticals

Forge green plus iconForge green minus icon

What is ARS Pharmaceuticals funding to date?

ARS Pharmaceuticals has raised $76.55MM to date.
Forge green plus iconForge green minus icon

When was ARS Pharmaceuticals founded?

ARS Pharmaceuticals was founded in 2015.
Updated on: Jun 12, 2022